C R Maxwell1, S J Kanes, T Abel, S J Siegel. 1. Stanley Center for Experimental Therapeutics in Psychiatry, Division of Neuropsychiatry, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA.
Abstract
OVERVIEW: All current antipsychotic medications work by binding to Gi-coupled dopamine (DA) D2 receptors. Such medications are thought to affect cellular function primarily by decreasing DA-mediated regulation of intracellular cyclic adenosine monophosphate (cAMP).However, several studies indicate that cAMP signal transduction abnormalities in schizophrenia may not be limited to D2-containing cells. The current study examines the potential of using non-receptor-based agents that modify intracellular signal transduction as potential antipsychotic medications. METHODS: The indirect DA agonist amphetamine has been used to model the auditory sensory processing deficits in schizophrenia. Such pharmacologically induced abnormalities are reversed by current antipsychotic treatments. This study examines the ability of the phosphodiesterase-4 inhibitor, rolipram, to reverse amphetamine-induced abnormalities in auditory-evoked potentials that are characteristic of schizophrenia. RESULTS: Rolipram reverses amphetamine-induced reductions in auditory-evoked potentials. CONCLUSION: This finding could lead to novel approaches to receptor-independent treatments for schizophrenia.
OVERVIEW: All current antipsychotic medications work by binding to Gi-coupled dopamine (DA) D2 receptors. Such medications are thought to affect cellular function primarily by decreasing DA-mediated regulation of intracellular cyclic adenosine monophosphate (cAMP).However, several studies indicate that cAMP signal transduction abnormalities in schizophrenia may not be limited to D2-containing cells. The current study examines the potential of using non-receptor-based agents that modify intracellular signal transduction as potential antipsychotic medications. METHODS: The indirect DA agonist amphetamine has been used to model the auditory sensory processing deficits in schizophrenia. Such pharmacologically induced abnormalities are reversed by current antipsychotic treatments. This study examines the ability of the phosphodiesterase-4 inhibitor, rolipram, to reverse amphetamine-induced abnormalities in auditory-evoked potentials that are characteristic of schizophrenia. RESULTS:Rolipram reverses amphetamine-induced reductions in auditory-evoked potentials. CONCLUSION: This finding could lead to novel approaches to receptor-independent treatments for schizophrenia.
Authors: Tatiana V Lipina; Oksana Kaidanovich-Beilin; Satish Patel; Min Wang; Steven J Clapcote; Fang Liu; James R Woodgett; John C Roder Journal: Synapse Date: 2011-03 Impact factor: 2.562
Authors: Noam D Rudnick; Andrew A Strasser; Jennifer M Phillips; Christopher Jepson; Freda Patterson; Joseph M Frey; Bruce I Turetsky; Caryn Lerman; Steven J Siegel Journal: Nicotine Tob Res Date: 2010-04-15 Impact factor: 4.244
Authors: Akinori Nishi; Mahomi Kuroiwa; Diane B Miller; James P O'Callaghan; Helen S Bateup; Takahide Shuto; Naoki Sotogaku; Takaichi Fukuda; Nathaniel Heintz; Paul Greengard; Gretchen L Snyder Journal: J Neurosci Date: 2008-10-15 Impact factor: 6.167